XIENCE Prime LL Everolimus Eluting Coronary Stent System - Drug-eluting coronary artery stent, non-biodegradable-polymer-coated

국가: 오스트레일리아

언어: 영어

출처: Department of Health (Therapeutic Goods Administration)

지금 구매하세요

Download 공공 평가 보고서 (PAR)
15-11-2017

제공처:

Abbott Vascular Division of Abbott Medical Australia Pty Ltd

수업:

Class III

Manufactured by:

Abbott Vascular Inc 3200 Lakeside Drive, SANTA CLARA, CA, 95054 United States Of America

치료 영역:

56284 - Drug-eluting coronary artery stent, non-biodegradable-polymer-coated

치료 징후:

Stenting system for coronary arteries, supplied pre-loaded onto an angioplasty balloon catheter. The XIENCE PRIME LL is intended to deliver and deploy a balloon-expandable, drug coated metal stent in the de novo and restenotic native coronary arteries. Five different stent diameters in two different lengths are available. Drug dose (micrograms) varies with stent size. Indicated for improving coronary luminal diameter in the following: Patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions; for restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset; for the treatment of patients with concomitant diabetes, acute coronary syndrome, due vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels (RVD equal to or < 2.77 mm), and in lesions where treatment results in the jailing of side branches (lesion with a side branch < 2 mm in diameter or equal

승인 상태:

A

승인 날짜:

2010-01-05

이 제품과 관련된 검색 알림